Year None202320222021202020192018201720162015201420132012 01.04.2023 Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 01.03.2023 Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directors 12.20.2022 Iveric Bio Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy 12.02.2022 Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11.30.2022 Iveric Bio Announces Pricing of $300 Million Public Offering of Common Stock 11.30.2022 Iveric Bio Announces Proposed Offering of Common Stock 11.17.2022 Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy 11.04.2022 Iveric Bio to Present at Upcoming Investor Conferences 11.03.2022 Iveric Bio Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy 11.03.2022 Iveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
